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Abstract
Background: Comorbidity increases overall mortality in patients diagnosed with hematological malignancies. The
impact of comorbidity on cancer-specific mortality, taking competing risks into account, has not been evaluated.
Methods: Using the Swedish Cancer Register, we identified patients aged >18 years with a first diagnosis of
acute myeloid leukemia (AML, N = 2,550), chronic myeloid leukemia (CML, N = 1,000) or myeloma (N = 4,584)
2002–2009. Comorbid disease history was assessed through in- and out-patient care as defined in the Charlson
comorbidity index. Mortality rate ratios (MRR) were estimated through 2012 using Poisson regression. Probabilities of
cancer-specific death were computed using flexible parametric survival models.
Results: Comorbidity was associated with increased all-cause as well as cancer-specific mortality (cancer-specific
MRR: AML = 1.27, 95 % CI: 1.15–1.40; CML = 1.28, 0.96–1.70; myeloma = 1.17, 1.08–1.28) compared with patients
without comorbidity. Disorders associated with higher cancer-specific mortality were renal disease (in patients
with AML, CML and myeloma), cerebrovascular conditions, dementia, psychiatric disease (AML, myeloma), liver
and rheumatic disease (AML), cardiovascular and pulmonary disease (myeloma). The difference in the probability of
cancer-specific death, comparing patients with and without comorbidity, was largest among AML patients <70 years,
whereas in myeloma the difference did not vary by age among the elderly. The probability of cancer-specific death
was generally higher than other-cause death even in older age groups, irrespective of comorbidity.
Conclusion: Comorbidities associated with organ failure or cognitive function are associated with poorer
prognosis in several hematological malignancies, likely due to lower treatment tolerability. The results highlight
the need for a better balance between treatment toxicity and efficacy in comorbid and elderly AML, CML and
myeloma patients.
Background
Survival from myeloid leukemia and myeloma has im-
proved during recent decades, but still more than
150,000 patients died of these malignancies worldwide
in 2012 [1, 2]. The incidence of most hematological
malignancies increases with age, as does the prevalence
of many non-malignant chronic disorders [3]. Although
patients with comorbid disease can be expected to have
a lower tolerance to standard chemotherapy-based
regimens used to treat hematological malignancies, evi-
dence to guide clinical decision making in these situa-
tions is poor. Clinical trials used as a basis for general
treatment recommendations provide insufficient guid-
ance for the treatment of patients with severe comorbid
disease since these patients are often underrepresented.
Among cancer patients in general, severe comorbid dis-
ease increases overall mortality [4], but results for cancer-
specific mortality are mixed [5–8]. In hematological
malignancies, multiple studies have established comorbid
disease overall as an independent predictor of all-cause
mortality [9–14], especially among patients eligible for
hematopoietic stem cell transplantation [15–17]. However,
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most of these studies exclude patients over 70 years of
age. Low socioeconomic status has been associated with
elevated mortality among patients with acute myeloid
leukemia (AML) and multiple myeloma [18], potentially
mediated through a more advanced disease at the time of
diagnosis, and/or through comorbid disease. Another po-
tential mediating factor between low SES and mortality is
access to health care services, although the Swedish social
security system does offer universal access of care.
For most hematological malignancies, it is not clear to
what extent specific comorbid diseases affect overall and
cancer-specific survival, and if effects differ by age. Such
estimations could guide clinicians in choosing the most
optimal treatments for these patients. E.g., if comorbid
disease would be associated with overall survival through
other-cause death rather than cancer-specific death, a
wait and watch strategy or low-intensity treatment may
be the best options. In this nationwide population-based
register study, we examined the impact of severe comor-
bid disease history (according to the Charlson comorbidity
index [19] and later modification [20]) on survival among
patients diagnosed with myeloid leukemia or myeloma in
Sweden 2002 to 2009. We also aimed to investigate poten-
tial variation in the effect of comorbidities on survival by
type of comorbid disease, type of hematological malig-
nancy and age.
Methods
In a prospective register-based cohort study, we identi-
fied all individuals aged > 18 years, diagnosed with a
first incident AML, chronic myeloid leukemia (CML)
or myeloma from 2002 to 2009 in the Swedish Cancer
Register (coverage > 95 % [21, 22]) using the Inter-
national Classification of Diseases (ICD), 10th revision
(Additional file 1, Table S1). Patients diagnosed at aut-
opsy or with a history of stem cell or solid organ transplant-
ation prior to the leukemia/myeloma diagnosis (n = 47)
were excluded. The study was approved by the Regional
Ethical Committee in Stockholm, Sweden (2010/1624–32).
Since we used de-identified register data, individual in-
formed consent was not sought in line with institutional
regulations.
Comorbid disease
The cohort was linked to the Swedish Patient Register
including in- and outpatient data (coverage 85–95 %
[23]) to collect dates of hospital visits and admissions,
and main and secondary diagnoses of comorbid disease
listed in the modified Charlson index [19, 20] with the
addition of psychiatric disorders (Additional file 1:
Table S1), during a period of 5 years prior to the diag-
nosis of leukemia/myeloma. Records of rheumatologic
and renal diseases were disregarded if they occurred dur-
ing the year leading up to the diagnosis of leukemia/
myeloma since their occurrence could be a sign of the yet
undiagnosed malignancy. Rheumatologic disorders only
recorded closely in time to a diagnosis of a hematological
malignancy may represent misclassified paramalignant
phenomena rather than true autoimmune/inflammatory
disease [24, 25]. Similarly, records of kidney dysfunction
shortly before myeloma diagnosis could be a sign of
myeloma rather than kidney disease [26]. Cancer his-
tory (excluding non-melanoma skin neoplasms) any
time prior to the leukemia/myeloma was identified in
the Swedish Cancer Register. Due to the possibility of
misclassification between subtypes of hematological
malignancies we excluded patients with prior history of
any hematological malignancy from the study cohort.
For patients with AML, we specifically noted a preced-
ing diagnosis of myelodysplastic disorders (MDS) or
myeloproliferative neoplasms (MPN).
Sociodemographic factors
Through the longitudinal integrated database for health
insurance and labor market (LISA), we assembled infor-
mation on educational level [27]. The highest achieved
educational level (< 10 years/10–12 years/ > 12 years) be-
fore diagnosis of leukemia/myeloma was used as a proxy
for socioeconomic status [28, 29].
Outcome
Patients were followed from the date of diagnosis of
leukemia/myeloma until emigration, death or December
31st 2012, whichever occurred first. Dates and causes of
death were obtained from the Cause-of-Death register
(coverage > 99 % [30]). Death records with ICD10 codes
for leukemia/myeloma as the main underlying cause of
death were treated as cancer-specific death, otherwise as
other-cause death (Additional file 1: Table S1). Leukemia-
myeloma-specific death was defined along the lines pro-
posed by Howlader et. al. [31] including a group of related
codes for cancer-specific death. In validation studies, the
information on main cause of death collected from
Swedish Cause of Death Register for malignant neo-
plasms has been highly accurate [30, 32].
Statistical methods
The associations of comorbid disease history and spe-
cific comorbidities with all-cause, cancer-specific and
other-cause death were estimated as mortality rate ra-
tios (MRR) with 95 % confidence intervals (CI) using
Poisson regression. When estimating the effect of spe-
cific comorbid diseases on survival, all patients without
the investigated type were included in the reference
group. All analyses were adjusted for follow-up time
(1-year intervals), age at diagnosis (10-year intervals),
sex, calendar year of diagnosis, country of birth and
education level. When assessing the statistical significance
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of interaction terms between comorbidity and time since
diagnosis, we found no evidence of non-proportional haz-
ards (p < 0.05). Moreover, for patients aged 60–89 years at
diagnosis, the probability of cancer-specific and other-
cause death was estimated in the presence of competing
risks, using estimates from flexible parametric survival
models [33]. These models use restricted cubic splines to
model the baseline cause-specific hazard rates. The fitted
models were stratified by age and sex, and used 3°-of-free-
dom to model the baseline hazard functions. All statistical
analyses were performed with STATA software version 13
(StataCorp. 2013. College Station, TX: StataCorp LP).
Results
We identified 2,550 patients with AML, 1,000 with CML
and 4,584 with myeloma diagnosed in Sweden between
2002 and 2009 (Table 1). Median age at diagnosis was
72 years in AML and myeloma, and 67 years in CML.
Median follow-up in AML was 0.6 (range 0–11) years,
in CML 4.2 (range 0–11) years, and in myeloma 3.1
(range 0–11) years. Approximately 40 % of the patients
had a history of comorbid disease (AML: 43 %; CML:
35 %; myeloma: 38 %) (Table 1). As expected, the preva-
lence of comorbidity increased with age and among pa-
tients diagnosed at 80+ years, more than half had a
history of comorbidity (AML and CML: 59 %, myeloma
52 %). Non-hematological cancers (13–15 %) and cardio-
vascular disease (10–14 %) were the most common co-
morbid disease groups (Table 1).
Most deaths were classified as cancer-specific, espe-
cially in AML (Additional file 2: Table S2). In general,
patients with a history of any of the specified comorbid
diseases had an increased rate of all-cause death com-
pared with patients without such history (Table 2). The
relative rate of other-cause death was higher than that of
cancer-specific death, although cancer-specific death was
also significantly increased among patients with comorbid
disease history compared to those without in AML and
myeloma, and borderline significantly increased among
CML patients. In addition, female sex and higher attained
education level tended to be associated with a more favor-
able prognosis (Table 2). Adjustment for age in 5-year
instead of 10-year intervals did not change the results.
Acute myeloid leukemia (AML)
A higher all-cause as well as cancer-specific mortality in
AML was observed for patients with previous cerebro-
vascular disease, rheumatologic diseases, renal disease,
liver disease and psychiatric disease (Fig. 1). Dementia
was also significantly associated with AML-specific mor-
tality. Renal disorders were associated with the highest
increase in mortality (MRR all-cause death = 3.10, 95 % CI:
1.96–4.89; MRR AML-specific death =2.46, 1.41–4.27, Fig. 1).
Two-hundred and fourteen AML patients (8.3 %) had a
prior record of MDS/MPN (MDS = 137, MPN = 77). Ad-
justment for previous MDS/MPN did not meaningfully
alter the associations between non-hematological co-
morbidities and cancer-specific mortality. To address the
relative contribution of prior cancer treatment, we also
analyzed outcomes in association with non-malignant
comorbidities separately, and results remained virtually
unchanged.
In analyses of the absolute impact of comorbid dis-
ease history in the age groups 60–69, 70–79 and 80–89
years by sex, the probability of dying from AML was
greater than the probability of dying from other causes
in both sexes and in all investigated age groups, irre-
spective of the presence of comorbid disease (Fig. 2,
Additional file 3: Table S3). The proportion of male pa-
tients aged 60–79 years who died from AML within the
first 5 years after diagnosis was significantly higher for
patients with at least one comorbid disease than for
those without (ages 60–69: 76 % vs 65 %, difference 11 %
(95 % CI 3.5–19); ages 70–79: 86 % vs 81 %, difference
4.8 % (95 % CI 1.5–7.9)) . Among patients 80–89 years,
comorbid disease history was not associated with a higher
cancer-specific probability of death (Fig. 2). For female pa-
tients aged 60–89 years, the pattern was similar, although
in the oldest group, AML-specific deaths encompassed a
larger share of all deaths as compared to males (Fig. 2,
Additional file 4: Table S4).
Chronic myeloid leukemia (CML)
In analyses of specific comorbid diseases, most tended
to be associated with a nominally higher all-cause as well
as CML-specific mortality, but numbers were low redu-
cing the precision. History of cardiovascular and renal
disorders and dementia were significantly associated
with all-cause death, whereas only renal disorders were
associated with increased risk of CML-specific death
(MRR = 7.47, 95 % CI: 1.66–33.6) (Fig. 1). Among men
70–89 years of age (but not those aged 60–69 years), the
probability of dying from causes other than CML was
greater than the probability of dying from CML within
5 years after diagnosis, regardless of the presence or
absence of comorbidity (Fig. 3). Among men 60–69
years, the 5-year probability of CML-specific death was
significantly higher for those with comorbid disease than
those without (31 vs 18 %, difference 12.6 %, 95 % CI:
2.5–22.7, Additional file 3: Table S3). In older age groups
there were no statistically significant differences in prob-
abilities of cancer-specific or other-cause death among
patients with and without comorbidities. In contrast,
among women, comorbid disease conferred a higher
probability of mainly cancer-specific death in ages 80–89
years (55 vs 41 %, difference 13.7, 95 % CI: 3.6–23.8) but
no significant differences in cancer-specific or other-
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Table 1 Characteristics of patients with AML, CML and myeloma, Sweden 2002–2009, and proportion with comorbid disease
AMLa CMLb Myeloma
All CDc All CDc All CDc
No (%) No (%) No (%) No (%) No (%) No (%)
Total 2550 (100) 1105 (43) 1000 (100) 350 (35) 4584 (100) 1735 (38)
Median follow up (year) 0.6 (0.0–11) 4.2 (0.0–11) 3.1 (0.0–11)
Sex
Women 1262 (50) 532 (42) 446 (45) 155 (35) 2075 (45) 745 (36)
Men 1288 (50) 573 (44) 554 (55) 195 (35) 2509 (55) 990 (39)
Age
18–49 336 (13) 50 (15) 210 (21) 19 (9) 219 (4.8) 32 (15)
50–59 307 (12) 82 (27) 147 (15) 26 (18) 605 (13) 121 (20)
60–69 505 (20) 204 (40) 208 (21) 72 (35) 1145 (25) 349 (30)
70–79 746 (29) 382 (51) 242 (24) 120 (50) 1499 (33) 651 (43)
80+ 656 (26) 387 (59) 193 (19) 113 (59) 1116 (24) 582 (52)
Median age (range) 72 (18–100) 67 (18–99) 72 (24–97)
Country of birth
Sweden 2279 (89) 996 (44) 881 (88) 313 (36) 4088 (89) 1553 (38)
Outside of Sweden 271 (11) 109 (40) 119 (12) 37 (31) 496 (11) 182 (37)
Education level
0–9 years 1065 (42) 533 (50) 376 (38) 163 (43) 1997 (44) 888 (44)
10–12 years 958 (38) 383 (40) 400 (40) 122 (31) 1612 (35) 557 (35)
> 12 years 464 (18) 157 (34) 204 (20) 57 (28) 897 (20) 264 (29)
Missing 63 (2.5) 32 (51) 20 (2.0) 8 (40) 78 (1.7) 26 (33)
No. of comorbid diseases
0 1445(57) 650 (65) 2849 (62)
1 732 (29) 225 (22) 1154 (25)
2+ 373 (15) 125 (12) 581 (13)
Types of comorbid diseases
Cancer 372 (15) 134 (13) 601 (13)
Cardiovascular disease 355 (14) 105 (10) 510 (11)
Diabetes 235 (9.2) 72 (7.2) 377 (8.2)
Cerebrovascular disease 200 (7.8) 54 (5.4) 262 (5.7)
Chronic pulmonary disease 148 (5.8) 51 (5.1) 243 (5.3)
Peripheral vascular disease 77 (3.0) 30 (3.0) 97 (2.1)
Peptic ulcer disease 51 (2.0) 30 (3.0) 110 (2.4)
Rheumatologic disease 82 (3.2) 20 (2.0) 71 (1.5)
Renal disease 22 (0.9) 5 (0.5) 55 (1.2)
Liver disease 20 (0.8) 8 (0.8) 44 (1.0)
Dementia 25 (1.0) 10 (1.0) 49 (1.1)
Psychiatric disorders 29 (1.1) 16 (1.6) 73 (1.6)
Hemiplegia/Paraplegia 5 (0.2) 3 (0.3) 31 (0.7)
AIDS/HIV 0 (0.0) 0 (0.0) 2 (0.04)
aAML acute myeloid leukemia, bCML chronic myeloid leukemia, cCD comorbid disease
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Table 2 MRRa for all-cause, cancer-specific and other-cause death among AML CML and myeloma patients, Sweden 2002–2009
AMLb MRR (95 % CI) CMLc MRR (95 % CI) Myeloma MRR (95 % CI)
All-cause death
Comorbid disease
No 1.00 1.00 1.00
Yes 1.39 (1.26–1.52) 1.64 (1.34–2.01) 1.40 (1.30–1.50)
No. of comorbid diseases
0 1.00 1.00 1.00
1 1.25 (1.12–1.38) 1.41 (1.12–1.77) 1.29 (1.19–1.40)
2+ 1.78 (1.57–2.02) 2.22 (1.71–2.88) 1.67 (1.51–1.85)
Sex
Men 1.00 1.00 1.00
Women 0.91 (0.84–1.00) 0.83 (0.69–1.02) 0.89 (0.83–0.95)
Education level
0–9 1.00 1.00 1.00
10–12 0.98 (0.89–1.09) 1.09 (0.89–1.35) 0.97 (0.89–1.04)
> 12 0.80 (0.70–0.91) 0.93 (0.70–1.25) 0.83 (0.75–0.92)
Cancer-specific death
Comorbid disease
No 1.00 1.00 1.00
Yes 1.27 (1.15–1.40) 1.28 (0.96–1.70) 1.17 (1.08–1.28)
No. of comorbid diseases
0 1.00 1.00 1.00
1 1.16 (1.04–1.29) 1.12 (0.81–1.55) 1.12 (1.02–1.23)
2+ 1.60 (1.39–1.83) 1.66 (1.13–2.44) 1.31 (1.15–1.48)
Sex
Men 1.00 1.00 1.00
Women 0.92 (0.84–1.01) 0.91 (0.70–1.20) 0.91 (0.84–0.99)
Education level
0–9 1.00 1.00 1.00
10–12 0.97 (0.87–1.08) 1.19 (0.89–1.58) 0.96 (0.88–1.06)
> 12 0.80 (0.69–0.91) 0.72 (0.46–1.12) 0.87 (0.78–0.97)
Other-cause death
Comorbid disease
No 1.00 1.00 1.00
Yes 2.64 (2.00–3.48) 2.14 (1.60–2.85) 2.22 (1.94–2.55)
No. of comorbid diseases
0 1.00 1.00 1.00
1 2.22 (1.64–3.01) 1.80 (1.30–2.49) 1.91 (1.64–2.23)
2+ 3.86 (2.72–5.47) 2.98 (2.07–4.30) 3.02 (2.53–3.62)
Sex
Men 1.00 1.00 1.00
Women 0.90 (0.69–1.16) 0.76 (0.58–1.01) 0.82 (0.72–0.94)
Education level
0–9 1.00 1.00 1.00
10–12 1.07 (0.79–1.43) 1.00 (0.73–1.36) 0.97 (0.83–1.13)
> 12 0.85 (0.58–1.25) 1.17 (0.80–1.73) 0.72 (0.58–0.88)
aMRR mortality rate ratios adjusted for age (in 10 year intervals), country of birth, time since diagnosis, calendar year of diagnosis and number of comorbid
diseases, sex and education level except when main effects of these factors were estimated, statistically significant results (p<0.05) are in bold. bAML acute
myeloid leukemia, cCML chronic myeloid leukemia
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Fig. 1 MRR for all-cause and cancer-specific death by type of comorbid disease. MRR mortality rate ratios adjusted for age (in 10 year
intervals), country of birth, time since diagnosis, calendar year of diagnosis and number of comorbid diseases, sex and education level
except when main effects of these factors were estimated. AML acute myeloid leukemia, CML chronic myeloid leukemia, CPD, chronic
pulmonary disease. *Because of few patients with hemiplegia/paraplegia (n = 49) and HIV/AIDS (n = 2) overall, and with liver disease in
CML, results for these groups are not presented
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cause death in younger age groups (Additional file 4:
Table S4).
Myeloma
A history of cardiovascular, cerebrovascular, chronic pul-
monary or renal disease, or dementia were associated
with a higher all-cause as well as myeloma-specific mor-
tality (Fig. 1). Liver and ulcer disease were additionally
associated with all-cause mortality whereas psychiatric
disease was associated with myeloma-specific mortality
only. No one with renal disease had a complementary
diagnosis code of amyloidosis.
All myeloma patient groups by sex and age (60–89
years) were more likely to die of myeloma than other
causes (Fig. 4). Irrespective of age at diagnosis and sex,
the 5-year probability of death from myeloma mainly,
Fig. 2 Stacked cumulative probability of cancer-specific and other-cause death among AML patients aged 60–89 years
Fig. 3 Stacked cumulative probability of cancer-specific and other-cause death, among CML patients aged 60–89 years
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but also of other-cause death, was significantly higher
among patients with comorbidities than among patients
without (Additional file 3: Table S3, Additional file 4:
Table S4). In absolute terms, the percentage differences
in the probabilities of patients who died from myeloma
within 5 years in the two groups with and without
comorbidity were moderate, ranging from 5.8 to 10.9
(Fig. 4).
Discussion
In this large population-based study, using prospectively
recorded information on comorbid diseases, we showed
that patients with a history of comorbidity at diagnosis
of AML, CML or myeloma had a higher all-cause but
also cancer-specific mortality compared with patients
without such history, reflecting an impact on disease-
specific outcome in these malignancies. Renal disorders
were associated with a markedly higher cancer-specific
mortality among all three patient groups (but were
uncommon, prevalence 0.5–1 %). Cerebrovascular dis-
ease, dementia and psychiatric disease were associated
with an increased risk of cancer-specific death in AML
and myeloma patients, liver and rheumatologic disease
increased risk in AML only, and cardiovascular and
chronic pulmonary disease in myeloma only. In abso-
lute terms, the 5-year probability of cancer-specific
death was greater than that of other-cause death among
all patients aged 60–89 years except among male pa-
tients > 70 years with CML. Comorbidity contributed
most to cancer-specific death among younger patients
(< 70 years) in AML, whereas the impact was constant
by age in myeloma.
AML
The achievement of complete remission and long-term
survival in AML mostly requires intensive combination
chemotherapy, and outcomes are strongly dependent
upon age and performance status [34, 35]. During the
study period in Sweden, the majority of the patients di-
agnosed up to the age of 80 years received intense treat-
ment [34]. Whether further prognostic stratification and
personalized therapy can be achieved by adding a more
systematic evaluation of comorbidity has been investi-
gated in a few previous studies. In most [12, 13, 36–38],
but not all [14] of these, comorbidity assessed using the
Charlson index was independently associated with a
worse overall survival. Etienne et al. (N = 133) showed
that comorbid diseases (with an index score > 1) nega-
tively predicted complete remission rate [13]. In two re-
cent large studies, a lower likelihood of treatment with
intense chemotherapy was noted in the presence of
comorbid disease [14, 37]. In Ostgard et al. [14], comor-
bidity was not associated with survival when adjusted for
performance status and other factors. Performance sta-
tus could however be considered an intermediate
explanatory factor rather than a true confounder and
therefore an association between comorbidity and sur-
vival through lower performance status is still plausible.
In that study, outcome was also investigated in relation
to specific comorbid disease, and dementia, heart failure
and renal failure were associated with opting-out of
Fig. 4 Stacked cumulative probability of cancer-specific and other-cause death, among myeloma patients aged 60–89 years
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intensive therapy [14]. This is in line with our findings
of a decreased cancer-specific survival in patients with
renal disease and dementia. A similar explanation is
plausible among patients with cerebrovascular and psy-
chiatric disease, also noted to have a worse cancer-
specific survival in our study.
Ostgard et al. also observed an indication of a stronger
association between comorbidity and outcome among
patients < 60 versus > 60 years of age. Extending these
previous results, we show a clear differential effect of co-
morbidity by age with a larger prognostic importance of
comorbidity among patients 60–69 years versus older
patients. Hence, our results provide additional support
for the notion that poor outcomes among AML pa-
tients > 70 years cannot be explained solely on the basis
of increased prevalence of comorbidity by age but [14, 34],
rather through a more general low treatment tolerance at
older ages.
CML
CML survival has improved greatly with the introduc-
tion of tyrosine kinase inhibitors such as imatinib (intro-
duced in 2001 in Sweden) [39] although elderly Swedish
CML patients (> 79 years) still have a 5-year relative
survival of only 60 % [40], that may reflect under-
implementation of tyrosine kinase inhibitor use [39, 40].
A few previous studies have shown a negative impact of
comorbidity on CML survival in line with our results,
mainly reflected in a poorer event-free survival [36] or
lower degree of complete cytogenic response [41, 42].
Previous studies have assessed comorbidity through
pooled indices including the Charlson comorbidity index
[36, 41], or the adult comorbidity evaluation-27 score
and cumulative illness rating scale [36, 41], but have not
investigated survival by specific comorbidities, perhaps
due to low numbers. We show for the first time that
prior renal disease is associated with a poorer cancer-
specific survival in CML. Renal disease is not an abso-
lute contraindication for use of tyrosine kinase inhibi-
tors, but glomerular filtration rate may decrease further
during tyrosine kinase inhibitors treatment [43]. Thus,
dose reductions [44] or caution to prescribe tyrosine kin-
ase inhibitors could potentially explain this finding. Also,
high comorbidity index has been associated with an in-
creased risk of toxicity to tyrosine kinase inhibitors in two
previous studies [41, 45].
A previous cohort study indicated that treatment of
elderly CML patients (n = 181, median age 79 years)
might be influenced by the individual physician’s per-
ception and could be improved by utilizing comorbidity
indices [36]. In our study, comorbidities were only as-
sociated with a higher probability of CML-specific
death among men 60–69 years of age but not among
older patients. Among the elderly males (> 70 years of
age), other-cause deaths outweighed CML-specific deaths
regardless of comorbidity. In contrast, among women with
CML, comorbidity was only associated with a higher
probability of CML-specific death in the oldest group
(80+). Women with CML were more likely to die of
CML-specific rather than other-cause death up to
89 years. Previous Swedish studies have noted a pos-
sible reluctance to treat elderly patients with tyrosine
kinase inhibitors during the investigated time-period
[39, 46]. The present findings indicate that CML out-
come could potentially be further improved among eld-
erly, especially female patients.
Myeloma
Survival in multiple myeloma has increased during re-
cent decades especially among younger patients (< 60-70
years), likely due to a combination of factors including
increasing use of high-dose Melphalan with stem cell
support and thalidomide as well as improvements in
supportive care [47, 48]. Previous studies have reported
comorbidities to be of critical prognostic importance at
myeloma diagnosis using different comorbidity indices
[49, 50]. In particular, renal impairment (pre-existing or
disease-related) has been identified as an important de-
terminant for myeloma outcome [50, 51]. Kleber et al.
have developed the Freiburg comorbidity index includ-
ing performance status, renal impairment and lung dis-
ease, and have reported large differences in overall
survival among 466 myeloma patients (median age
62 years) by the presence or absence of a combination of
these factors [49]. In our study including ~ 4,500 mye-
loma patients with a median age of 72 years, we confirm
the adverse prognostic impact of pre-existing renal and
pulmonary disease, and extend the list of disorders asso-
ciated with a higher risk of cancer-specific death to also
include cardiovascular and cerebrovascular disease, de-
mentia and psychiatric disorders. Hence, our study sug-
gests that future evaluations of comorbidity and
myeloma outcome in larger studies may benefit from
including a broader list of disorders [52]. Interestingly,
and in contrast with AML and CML, the prognostic im-
pact of comorbid disease seemed relatively constant by
age (among patients aged 60–89 years) [53].
The strengths of our study include the large size of the
cohort, the high quality and coverage of the registers
used as well as the population-based unselected setting,
evaluating the effect of 12 severe comorbid diseases on
outcome of hematological malignancies in the most re-
cent decade. We also, for the first time in this setting,
used a novel methodology to estimate probabilities of
death associated with comorbidities in patients with
hematological malignancies, in the presence of compet-
ing risks. While traditional ratio estimates of net survival
(such as those presented in Table 2) are important to
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identify and evaluate the impact of prognostic factors as-
sociated with the disease under study, competing risks
analyses may provide additional insights to understanding
the real-world prognosis of the patients. This is because,
in contrast to estimates of net survival, a competing risks
analysis takes into account that causes other than the ma-
lignancy may kill the patient first and thereby preclude
death from the malignancy. Thus, competing risks ana-
lyses more appropriately reflect the absolute impact of a
prognostic factor on prognosis [54]. The advantage of
studying the three different hematological malignancies
together was to contrast between malignancy types need-
ing intensive treatment upfront (AML) and those with
slower tumor progression in need of more intermediate-
intensity treatment (myeloma, CML). An important limi-
tation of our study was the lack of clinical data such as
performance status, disease-specific prognostic determi-
nants including genetic abnormalities, and treatment.
Since prior comorbidity may lead to lower performance
status and may affect choices of treatment, rather than the
other way around, performance status and treatment
intensity may be considered explanatory factors rather
than true confounders when estimating the impact of co-
morbidity on survival. Another limitation to consider is
the definition of deaths as cancer-specific. Although the
accuracy of the classification of main underlying cause of
death has been found to be high for malignant diseases
in the Swedish Cause-of-death registers [30, 32], some
leukemia/myeloma deaths may have been erroneously
classified as non-cancer-related or vice versa. However,
given that the majority of the deaths were cancer-
specific and that we also present patterns of all-cause
and other-cause deaths, a minor degree of such mis-
classification does not threaten our main conclusions.
Conclusion
Patients with AML, CML and myeloma have a high
prevalence of comorbid disease especially in older ages.
In the present study, comorbidities associated with
worse cancer-specific mortality primarily included dis-
eases associated with organ failure and with reduced
cognitive function. Several comorbid diseases were asso-
ciated with higher AML-specific and myeloma-specific
mortality, whereas in CML, only renal disease was asso-
ciated with a worse cancer-specific outcome. The impact
of comorbidity varied by age and was most pronounced
among AML patients younger than 70 years. Cancer-
specific deaths outnumbered other-cause deaths in all
patient groups except male patients with CML above
70 years of age. The results highlight the need for clin-
ical awareness around comorbid patient groups and pa-
tient information, as well as an urgent need for the
development and evaluation of alternative effective but
less toxic treatment regimens.
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